Lietman, Caressa D. http://orcid.org/0000-0003-3863-2751
McKean, Meredith http://orcid.org/0000-0003-0944-7418
Article History
Received: 17 September 2021
Revised: 23 December 2021
Accepted: 31 January 2022
First Online: 18 February 2022
Conflict of interest
: CL has no competing financial interest to disclose. MM has the following competing interests: Research Grants—Paid to Institution—Ascentage Pharma Group, Bicycle Therapeutics, Dragonfly Therapeutics, Epizyme, Exelixis, Genentech, GlaxoSmithKline, IDEAYA Biosciences, Ikena Oncology, Infinity Pharmaceuticals, Jacobio Pharmaceuticals, Moderna, NBE Therapeutics, Novartis, Oncorus, Plexxikon, Prelude Therapeutics, Regeneron, Sapience Therapeutics, Seattle Genetics, Tizona Therapeutics, TMUNITY Therapeutics, TopAlliance Biosciences, Bayer, BioMed Valley Discoveries, EMD Serono, MedImmune, Nektar Therapeutics, Pfizer, Teneobio, Arvinas, Tempest Therapeutics, Arcus Biosciences, Synthorax, Alpine Immune, Scholar Rock, BioNTech, Erasca, Kechow Pharma, Mereo BioPharma, Foghorn Therapeutics, Pyramid Biosciences, PACT pharma, ImmVira Pharma, Kinnate Biopharma, Metabomed. Consulting/Advisory Role—Paid to Institution—Array BioPharma, AstraZeneca, MedPage Today, Pfizer, Regeneron Pharmaceuticals, Astellas Pharma, BicycleTx Limited, Castle Biosciences, Ideaya Biosciences, iTeos.